Online inquiry

6-Thioguanosine-containing Cap

Background 6-Thioguanosine-containing Cap Services Highlights FAQs Published Data

Background

mRNA cap is a unique mark that involves specific mRNA processing and translation initiation. Many mRNA studies require reliable preparation and modification of 5'-capped RNAs. As a customer-oriented CRO company, Creative Biolabs provides a comprehensive range of customized, high-quality mRNA services in vaccine and therapeutics development to support the pharmaceutical industry and related biomedical sciences research communities worldwide.


  • Introduction of 6-Thioguanosine-containing Cap

The classical cap structure is a 7-methylguanosine moiety connected to the mRNA via a triphosphate linkage at 5'-end (m7GpppG or m7G). It can be recognized by several specialized proteins involved in mRNA transport, translation, translational repression and degradation. 6-thioguanosine (s6G) is a photosensitive molecule that can photo-crosslink to both proteins and nucleic acids to study cap-protein and cap-nucleic acid interactions at the molecular level.

s6G is suitable for the preparation of capped RNAs by in vitro transcription (IVT) because this modification into mRNA cap confers resistance to Dcp1/2 (mRNA decapping) and stabilizes interaction with eIF4E, resulting in increased translational efficiency and half-life of mRNA. Moreover, s6G modification is a useful tool for structural and functional studies of RNAs, including the activity of ribonuclease P, interaction of cap analogs, triplexes formation, RNA sequencing, and population dynamics.

1.Simplified diagram of the 6-thioguanosine capping structure.

Fig.1 6-Thioguanosine capping.

6-Thioguanosine-containing Cap Services

Creative Biolabs is committed to meeting your specific requirements for synthetic mRNA. We have developed one all-around platform for mRNA in vitro transcription, mRNA modification, mRNA delivery, mRNA stability test, mRNA structure prediction, mRNA-based cell reprogramming, etc. Our high-quality services address the unmet needs in synthetic mRNA for rapidly growing research and clinical uses. For mRNA modification, we not only provide 5' capping and 3' poly (A) tailing service, but also provide 5' or 3' UTR (Kozak sequence) for improved translation efficiency. Especially, we provide two capping options for the covalent linkage of s6G to RNA for your choice:

  • Post-transcriptional enzymatic labeling: higher efficiency, nearly 100%.
  • Cotranscriptional enzymatic labeling: a single-step workflow with permits non-canonical cap structures.
2.Structural schematic diagram of cap analogues containing 6-Thioguanosine.

Fig.2 Structure of cap analogs containing 6-thioguanosine.1

Inquire About Our Services

Highlights

  • Guaranteed mRNA quantity with a customizable panel of QC tests
  • Flexible choice of options depending on the use of mRNA (e.g. 5' capping & 3' poly (A) tail option)
  • High efficiency of 5'-capping with a variety of capping moieties
  • Suitable price with a short turnaround time

FAQ

Q: What is a 6-Thioguanosine-containing cap?

A: It is a modified mRNA cap incorporating 6-thioguanosine (s6G), used to enhance mRNA stability and study mRNA interactions.

Q: Why use 6-Thioguanosine in mRNA capping?

A: s6G increases mRNA stability, resists decapping enzymes, and facilitates photo-crosslinking to study RNA-protein and RNA-nucleic acid interactions.

Q: What are the applications of s6G-containing caps?

A: Applications include RNA interaction studies, structural and functional RNA research, and improved mRNA stability for therapeutics.

Q: How is the s6G cap added to mRNA?

A: It can be incorporated either co-transcriptionally or post-transcriptionally using enzymatic labeling techniques.

Q: What methods are used to verify the incorporation of 6-thioguanosine caps?

A: High-performance liquid chromatography (HPLC) and mass spectrometry are used for verification.

Q: What support does Creative Biolabs offer for custom 6-thioguanosine capping projects?

A: They provide comprehensive consultation, design, and optimization services tailored to client needs.

Published Data

The article investigates the effects of incorporating 6-thioguanosine (s6G) into RNA duplexes. It explores how s6G influences the thermodynamic stability and structural properties of RNA. The study reveals that s6G generally decreases the stability of RNA duplexes, though the extent of destabilization depends on its position within the sequence. When s6G is located at terminal positions, it has a weaker destabilizing effect compared to internal positions. Despite these changes in stability, structural analysis using NMR and circular dichroism indicates that the overall RNA duplex structure remains largely unaffected. These findings are significant for understanding RNA behavior and designing RNA-based therapeutics and research tools.

3.NMR analysis results of four different RNA double strands containing s6G.

Fig.3 NMR analysis of s6G-containing RNA duplexes.2

Featured mRNA Products

Hot IVT Vectors

Cat. No Product Name Promoter
CAT#: GTVCR-WQ001MR IVTScrip™ pT7-mRNA-EGFP Vector T7
CAT#: GTVCR-WQ002MR IVTScrip™ pT7-VEE-mRNA-EGFP Vector T7
CAT#: GTVCR-WQ003MR IVTScrip™ pT7-VEE-mRNA-FLuc Vector T7
CAT#: GTVCR-WQ87MR IVTScrip™ pT7-VEE-mRNA-Anti-SELP, 42-89-glycoprotein Vector T7

Hot IVTScrip™ mRNA Transcript

Cat. No Product Name Type
CAT#: GTTS-WQ001MR) IVTScrip™ mRNA-EGFP (Cap 1, 30 nt-poly(A)) Reporter Gene
CAT#: GTTS-WK18036MR IVTScrip™ mRNA-Human AIMP2, (Cap 1, Pseudo-UTP, 120 nt-poly(A)) Enzyme mRNA
(CAT#: GTTS-WQ004MR) IVTScrip™ mRNA-Fluc (Cap 1, 30 nt-poly(A)) Reporter Gene
(CAT#: GTTS-WQ009MR) IVTScrip™ mRNA-β gal (Cap 1, 30 nt-poly(A)) Reporter Gene

Featured mRNA Services

References

  1. Nowakowska, M.; et al. Cap analogs containing 6-thioguanosine-reagents for the synthesis of mRNAs selectively photo-crosslinkable with cap-binding biomolecules. Organic & biomolecular chemistry. 2014, 12(27): 4841-4847.
  2. Gładysz, Michał, et al. "Thermodynamic and structural contributions of the 6-thioguanosine residue to helical properties of RNA." Scientific Reports 9.1 (2019): 4385.
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW